Using pharmacologic reactive oxygen species (ROS) inhibitors and NADPH oxidase 2-null neutrophils, investigators found that ROS depletion specifically suppresses growth of androgen-insensitive prostate cancer cells.
[Clinical & Experimental Metastasis]